Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Biotechnology

Healthcare
$9.07 -1.39%

-$0.26 today

Market cap
$775.03M
Beta
1.60
P/E (TTM)
-9.1
EPS (TTM)
-$1.98
52W Low $4.12High $25.77

Volume 1.26M

Average 1.02M

GLUE Net Income

Bottom-line profit after all expenses, interest, and taxes.

Monte Rosa Therapeutics, Inc.NASDAQ: GLUE

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$44.5M, compared with $46.89M a year earlier. Trailing-twelve-month net income was -$130.01M.

Context

  • Net income amounted to 31.2% of revenue in FY2025, down 64.9 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$57.83M (-49.7%) for the fiscal year ending Dec 2026, a slowdown from the +46.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$44.5M+3.5% QoQ
Last fiscal yearDec 2025
-$38.63M+46.9% YoY
LTMMar 2026
-$130.01M-2213.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-194.9%-236.1%-41.2 pp
1 year+46.9%-49.7%-96.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(38.63M) USD
Year-over-year change
+46.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GLUE compares with its peers on the latest reported figures

  • GLUE's LTM Mar 2026 net income of -$130.01M is the 3rd highest of the 4 companies compared; the peer median is -$103.8M.
  • Its year-over-year change of -2213.0% is the lowest of 4, against a peer median of -0.5%.
  • Net income amounts to 302.7% of revenue for GLUE, versus a peer median of 247.5%.
GLUE Competitors Peer median
Net Income for GLUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$294.88M +220.5%—42.0%
CCCCC4 Therapeutics, Inc.LTM Mar 2026-$103.8M -0.5%—297.8%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-$130.01M -2213.0%—302.7%
ARVNArvinas, Inc.LTM Mar 2026-$221.3M -374.9%—247.5%
Peer median (excluding GLUE) -$103.8M-0.5%—247.5%

Competitors are the stored peer set for GLUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00075.62M123.67M
Cost of Revenue006.22M8.12M8.36M
Gross Profit00(6.22M)67.5M115.32M
Gross Margin———89.3%93.2%
Research & Development57.16M85.06M105.05M121.56M141.5M
Selling, General & Admin15.73M27.32M32.04M35.17M36.38M
Operating Expenses72.88M112.38M137.09M148.61M169.52M
Depreciation & Amortization2.13M3.75M6.22M8.12M8.36M
EBITDA(71.83M)(100.99M)(128.79M)(62.01M)(31.37M)
EBITDA Margin———-82.0%-25.4%
Operating Income(72.88M)(112.38M)(143.31M)(81.11M)(54.21M)
Operating Margin———-107.3%-43.8%
Interest Income46K3.76M9.33M10.57M12.94M
Interest Expense03.76M000
Other Income / Expenses(1.08M)3.88M8.3M10.98M14.49M
Income Before Tax(73.96M)(108.5M)(135.01M)(70.13M)(39.72M)
Pre-Tax Margin———-92.7%-32.1%
Income Tax Expense00338K2.57M(1.1M)
Net Income(73.96M)(108.5M)(135.35M)(72.7M)(38.63M)
Net Margin———-96.1%-31.2%
EPS (Basic)(1.59)(2.30)(2.63)(0.98)(0.46)
EPS (Diluted)(1.59)(2.30)(2.63)(0.98)(0.46)
Weighted Avg Shares46.54M47.23M51.4M73.91M83.07M
Weighted Avg Shares (Diluted)46.54M47.23M51.4M73.91M83.07M

Monte Rosa Therapeutics, Inc.

NASDAQ:GLUE

Intrinsic Alpha fair value

Locked

Current Price

$9.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.